IL-6 anticorps

N° du produit ABIN1383944

Détail du produit anti-IL-6 anticorps

Antigène: IL-6 (IL6) (Interleukin 6 (IL6))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp IL-6 est non-conjugé

Application: ELISA, Flow Cytometry (FACS), Functional Studies (Func), ELISpot

Specificité: Recognises both natural and recombinant human IL-6

Purification: Ion exchange chromatography

Stérilité: 0.22 μm filtered

Immunogène: Recombinant human IL-6,Myeloma X63/AG.8653 x Balb/c spleen cells

Clone: B-E8

Isotype: IgG1 kappa

Biological Activity Comment: Inhibits IL-6 induced proliferation on XG1 Cell line

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free

Agent conservateur: Without preservative

Stock: 4 °C

Stockage commentaire: Stable at +2-8°C for 12 months. For longer storage freeze aliquots.

Références pour anticorps anti-IL-6 (ABIN1383944)

Sprynski, Hose, Caillot, Réme, Shaughnessy, Barlogie, Seckinger, Moreaux, Hundemer, Jourdan, Meissner, Jauch, Mahtouk, Kassambara, Bertsch, Rossi, Goldschmidt, Klein: "The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor." dans: Blood, Vol. 113, Issue 19, pp. 4614-26, (2009) (PubMed).

Adam, Rabe, Suthaus, Grötzinger, Rose-John, Scheller: "Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor." dans: Journal of virology, Vol. 83, Issue 10, pp. 5117-26, (2009) (PubMed).

Moreau, Garban, Attal, Michallet, Marit, Hulin, Benboubker, Doyen, Mohty, Yakoub-Agha, Leyvraz, Casassus, Avet-Loiseau, Garderet, Mathiot, Harousseau: "Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma." dans: Blood, Vol. 112, Issue 9, pp. 3914-5, (2008) (PubMed).

Garban, Attal, Michallet, Hulin, Bourhis, Yakoub-Agha, Lamy, Marit, Maloisel, Berthou, Dib, Caillot, Deprijck, Ketterer, Harousseau, Sotto, Moreau: "Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma." dans: Blood, Vol. 107, Issue 9, pp. 3474-80, (2006) (PubMed).

Moreau, Hullin, Garban, Yakoub-Agha, Benboubker, Attal, Marit, Fuzibet, Doyen, Voillat, Berthou, Ketterer, Casassus, Monconduit, Michallet, Najman, Sotto, Bataille, Harousseau: "Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol." dans: Blood, Vol. 107, Issue 1, pp. 397-403, (2005) (PubMed).

Song, Torphy, Griswold, Shealy: "Coming of age: anti-cytokine therapies." dans: Molecular interventions, Vol. 2, Issue 1, pp. 36-46, (2004) (PubMed).

Moreaux, Legouffe, Jourdan, Quittet, Rème, Lugagne, Moine, Rossi, Klein, Tarte: "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone." dans: Blood, Vol. 103, Issue 8, pp. 3148-57, (2004) (PubMed).

Derhaschnig, Bergmair, Marsik, Schlifke, Wijdenes, Jilma: "Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia." dans: Critical care medicine, Vol. 32, Issue 5, pp. 1136-40, (2004) (PubMed).

Smith, Barg, Weedon, Papengelis, Smeets, Tak, Kraan, Coleman, Ahern: "Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints." dans: Annals of the rheumatic diseases, Vol. 62, Issue 4, pp. 303-7, (2003) (PubMed).

Ancey, Menet, Corbi, Fredj, Garcia, Rücker-Martin, Bescond, Morel, Wijdenes, Lecron, Potreau: "Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation." dans: Cardiovascular research, Vol. 59, Issue 1, pp. 78-85, (2003) (PubMed).

Choy: "Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis." dans: Annals of the rheumatic diseases, Vol. 62 Suppl 2, pp. ii68-9, (2003) (PubMed).

Derenne, Monia, Dean, Taylor, Rapp, Harousseau, Bataille, Amiot: "Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells." dans: Blood, Vol. 100, Issue 1, pp. 194-9, (2002) (PubMed).

Delneste, Charbonnier, Herbault, Magistrelli, Caron, Bonnefoy, Jeannin: "Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages." dans: Blood, Vol. 101, Issue 1, pp. 143-50, (2002) (PubMed).

Leblond, Dhedin, Mamzer Bruneel, Choquet, Hermine, Porcher, Nguyen Quoc, Davi, Charlotte, Dorent, Barrou, Vernant, Raphael, Levy: "Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders." dans: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 19, Issue 3, pp. 772-8, (2001) (PubMed).

Jego, Bataille, Pellat-Deceunynck: "Interleukin-6 is a growth factor for nonmalignant human plasmablasts." dans: Blood, Vol. 97, Issue 6, pp. 1817-22, (2001) (PubMed).

Menetrier-Caux, Thomachot, Alberti, Montmain, Blay: "IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells." dans: Cancer research, Vol. 61, Issue 7, pp. 3096-104, (2001) (PubMed).

Corbellino, Bestetti, Scalamogna, Calattini, Galazzi, Meroni, Manganaro, Fasan, Moroni, Galli, Parravicini: "Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy." dans: Blood, Vol. 98, Issue 12, pp. 3473-5, (2001) (PubMed).

Haddad, Paczesny, Leblond, Seigneurin, Stern, Achkar, Bauwens, Delwail, Debray, Duvoux, Hubert, Hurault de Ligny, Wijdenes, Durandy, Fischer: "Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial." dans: Blood, Vol. 97, Issue 6, pp. 1590-7, (2001) (PubMed).

Kube, Holtick, Vockerodt, Ahmadi, Haier, Behrmann, Heinrich, Diehl, Tesch: "STAT3 is constitutively activated in Hodgkin cell lines." dans: Blood, Vol. 98, Issue 3, pp. 762-70, (2001) (PubMed).

Foussat, Wijdenes, Bouchet, Gaidano, Neipel, Balabanian, Galanaud, Couderc, Emilie: "Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes." dans: European cytokine network, Vol. 10, Issue 4, pp. 501-8, (2000) (PubMed).

Détails sur IL-6

Antigène: IL-6 (IL6) (Interleukin 6 (IL6))

Autre désignation: IL-6 (IL6 Produits)

Pathways: Signalisation TLR, Hormone Transport, Negative Regulation of Hormone Secretion, Myometrial Relaxation and Contraction, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Regulation of Carbohydrate Metabolic Process, Autophagy, Cell RedoxHomeostasis, Cancer Immune Checkpoints, Inflammasome